Reference : Fluoxetine therapy in obese diabetic and glucose intolerant patients.
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/14024
Fluoxetine therapy in obese diabetic and glucose intolerant patients.
English
Kutnowski, M. [> > > >]
Daubresse, J. C. [> > > >]
Friedman, H. [> > > >]
Kolanowski, J. [> > > >]
Krzentowski, G. [> > > >]
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Van Gaal, L. [> > > >]
1992
International Journal of Obesity & Related Metabolic Disorders
Nature Publishing Group
16 Suppl 4
S63-6
0307-0565
1476-5497
London
United Kingdom
[en] Blood Glucose/metabolism ; Diabetes Mellitus/blood/drug therapy/physiopathology ; Double-Blind Method ; Female ; Fluoxetine/adverse effects/therapeutic use ; Glucose Tolerance Test ; Hemoglobin A, Glycosylated/analysis ; Humans ; Hyperglycemia/blood/physiopathology ; Insulin/blood ; Male ; Middle Aged ; Obesity/blood/drug therapy/physiopathology ; Placebos ; Weight Loss
[en] A double-blind placebo-controlled trial was conducted, involving 97 obese diabetic and glucose intolerant patients receiving either 60 mg fluoxetine daily (47 patients) or a placebo (50 patients); a similar calorie-restricted diet was prescribed to all patients. Weight loss was significantly higher in the fluoxetine-treated patients, whose diabetic status improved. Drop-out rate was not significantly different for both groups of patients.
http://hdl.handle.net/2268/14024

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.